Insider Buying: NewGenIvf Group (NASDAQ:NIVF) Director Acquires 2,500,000 Shares of Stock

NewGenIvf Group Limited (NASDAQ:NIVF) Director Kong Yiu Cheung purchased 2,500,000 shares of the stock in a transaction that occurred on Monday, July 27th. The stock was bought at an average cost of $1.00 per share, for a total transaction of $2,500,000.00. Following the acquisition, the director directly owned 3,722,223 shares in the company, valued at $3,722,223. This trade represents a 204.55% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Kong Yiu Cheung also recently made the following trade(s):

• On Thursday, June 18th, Kong Yiu Cheung bought 500,000 shares of NewGenIvf Group stock. The shares were bought at an average price of $1.33 per share, for a total transaction of $665,000.00.

NewGenIvf Group Price Performance

Shares of NASDAQ:NIVF opened at $1.33 on Wednesday. NewGenIvf Group Limited has a one year low of $1.15 and a one year high of $1,539.00. The firm has a fifty day moving average price of $2.96 and a two-hundred day moving average price of $11.34. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.12 and a quick ratio of 2.98.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on NIVF shares. Wall Street Zen upgraded shares of NewGenIvf Group to a “hold” rating in a research report on Saturday, July 4th. Weiss Ratings restated a “sell (d)” rating on shares of NewGenIvf Group in a report on Friday, July 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

NewGenIvf Group Company Profile

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.